Portal do Butantan

Preliminary results of the clinical trials on phase 3 in Chile demonstrates that CoronaVac is efficient for children and teenagers between three and 17 years of age

Publicado em: 01/01/1970

The preliminary results of the clinical trial on phase 3 in Chile has been demonstrating that CoronaVac is efficient for the population with age between 3 and 17. According to the researcher and professor of the Pontifical Catholical University from Chile, Susan Bueno, who presented the data during her participation in the third day of the CoronaVac Symposium, the first reports also indicates a small number of adverse events.

“The efficacy, or the data from the real life that were already provided by the Public Health Institute from Chile, shows that vaccinated kids with six or more years of age did not have serious adverse events, which is something very positive”, informed Susan, punctuating that CoronaVac is an excellent vaccine to use on children, specially above three years of age.

The preliminary reports of the clinical studies of the phase 3 regarding CoronaVac on Chile, that is being conducted by the Millenium Immunology and Immunotherapy Institute of the  Pontifical Catholical University from Chile, demonstrate that children presented a higher production of antibodies than the adults and less adverse reactions.

Until this moment, the most cases reported on children that took part in the clinical trials are pain and redness on the area of the injection, which means, light cases of level 1. Regarding the non immediate adverse events, the researcher said that were reported fever, cough and nauseas in a small part of the group.

The research, made in partnership with other institutions from other countries, recruited 14 thousand volunteers. In Chile, the patients were separated in groups to evaluate the immunogenicity of the vaccine and use of placebo. By the end of the study will be evaluated the total number of antibodies, neutralizing antibodies and the emerge of antibodies for another antigens.

“At this moment we evaluate the increase of IGG on the saliva after the first dose, at the moment of the second dose and 2 weeks after the second dose. With that preliminary data, we can detect on the saliva an increase of IGG levels anti-S1”, affirmed the researcher.

The average age of the patients is 6,43 years old, separated into boys and girls. The older groups  have a minor number of volunteers because the use of the vaccine for the group age above 12 years old have already been approved in Chile.  In September, the regulatory agency of medicine from Chile approved the use of CoronaVac on children that are also above the group age of 6 years.